The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider ...read more
Adagene, a Phase 1 biotech developing antibody cancer immunotherapies in China, raised $140 million by offering 7.4 million ADSs at $19, the high end of the range of $17 to $19. Adagene's proprietary AI-Powered DPL platform explores the dynamic...read more
Updated Monday, 2/8. The IPO market is buzzing with 15 IPOs slated to raise $4.0 billion in the week ahead, led by dating app Bumble’s billion-dollar offering. Bumble (BMBL) plans to raise $1.7 billion at a $7.5...read more
Adagene, a Phase 1 biotech developing antibody cancer immunotherapies in China, announced terms for its US IPO on Wednesday. The Suzhou, China-based company plans to raise $132 million by offering 7.4 million ADSs at a price range of $17 to $19. At the...read more
US IPO Weekly Recap: IPO frenzy brings the year’s largest deal and biggest pop in a 17 IPO week
The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider ...read more
Chinese cancer biotech Adagene prices US IPO at $19 high end
Adagene, a Phase 1 biotech developing antibody cancer immunotherapies in China, raised $140 million by offering 7.4 million ADSs at $19, the high end of the range of $17 to $19. Adagene's proprietary AI-Powered DPL platform explores the dynamic...read more
US IPO Week Ahead: Bumble’s billion-dollar deal leads a buzzy 15 IPO week
Updated Monday, 2/8. The IPO market is buzzing with 15 IPOs slated to raise $4.0 billion in the week ahead, led by dating app Bumble’s billion-dollar offering. Bumble (BMBL) plans to raise $1.7 billion at a $7.5...read more
Chinese cancer biotech Adagene sets terms for $132 million US IPO
Adagene, a Phase 1 biotech developing antibody cancer immunotherapies in China, announced terms for its US IPO on Wednesday. The Suzhou, China-based company plans to raise $132 million by offering 7.4 million ADSs at a price range of $17 to $19. At the...read more